Clinical Trial Update: SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

View source ↗

Summary

A retrospective cohort study sponsored by AstraZeneca assesses PD-L1 expression in recurrent and metastatic squamous cell carcinoma of the head and neck.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Snippet

Sponsor: AstraZeneca | Conditions: Squamous Cell Carcinoma of the Head and Neck | Status: COMPLETED